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Adhatoda  zeylanica  is a dietary  supplement  ingredient  present  in several  types  of dietary  supplements,
including  weight  loss,  respiratory  relief,  and immune  regulating  products.  Due  to its reported  wide  range
of uses  in  folk  medicine,  it was  hypothesized  that it may  have  the potential  to target  multiple  organs  and
lead  to  a range  of  toxicity  features.  As  a preliminary  evaluation  of  the  safety  of  this  herbal  ingredient,  an
investigation  into  its  effects  on the  kidney  was  sought.  An in  vitro  study  of  its  potential  nephrotoxicity




capture  both  general  forms  of cellular  toxicity  as well  as ones  that  are  speciﬁc  to  proximal  tubules.  A.
zeylanica  was  only  capable  of  inducing  detrimental  short-term  toxicity  to  HK-2 cells  at relatively  high
treatment  concentrations  when  exposed  directly  to the cells.  The  lack  of  acute  and  potent  toxicity  of A.
zeylanica  under  our  experimental  conditions  calls  for further  studies  to better  deﬁne  its toxicant  threshold
and  establish  safe dosage  levels.
Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC  BY-NC-ND  license. Introduction
According to the Dietary Supplement Health and Education
ct [11], supplement ingredients sold in the United States before
ctober 15, 1994 are presumed to be safe and are therefore not
equired to be reviewed by the FDA. Any ingredient sold after this
ate is classiﬁed as a “new ingredient” and its manufacturer must
how how it determined that reasonable evidence exists for safe
uman use. In effect, dietary supplements do not undergo strin-
ent safety testing, leaving open the possibility of having unsafe
upplement products on the market. Indeed, not only have several
ietary supplements been recalled in recent years, but many even
ontinue to be sold months after their recalls [8].
Despite the potential risk of having unsafe dietary supplements
lready on the market, it is reported that supplement use among
merican consumers has increased signiﬁcantly in recent years
1,4]. Furthermore, supplements that use botanical ingredients now
omprise a signiﬁcant portion of the market, with current use in
Abbreviations: ROS, reactive oxygen species; MMP,  mitochondrial membrane
otential; B2 M,  beta-2-microglobulin; KIM-1, kidney injury molecule-1.
∗ Corresponding author at: US FDA, MOD-1 Laboratories, 8301 Muirkirk Rd., HFS-
25, Lab 1406, Laurel, MD 20708, United States.
E-mail address: miriam.mossoba@fda.hhs.gov (M.E. Mossoba).
ttp://dx.doi.org/10.1016/j.toxrep.2015.11.005
214-7500/Published by Elsevier Ireland Ltd. This is an open access article under the CC B(http://creativecommons.org/licenses/by-nc-nd/4.0/).
the United States increasing steadily [29]. This growing popular-
ity of botanical dietary supplements may  be related to a common
belief among consumers that natural herbal remedies are safer
alternatives to prescription drugs. One such supplement type is
made from the herb Adhatoda zeylanica (A. zeylanica; also referred
to as Adhatoda vasica or Malabar nut), which is currently used as
an ingredient in a dozens of dietary supplements claiming to sup-
port weight loss, respiratory relief, or immune system health [19].
A. zeylanica consists of many types of alkaloids including vasici-
none, vasicine, adhatonine, adhatodine, vasicinol, and vasicinolone
[3,14,25], whose reported effects may  help account for their use
as ingredients in dietary supplements. Vasicinone and vasicine, for
example, possess antiphylactic functions to possibly help control
immune activation responses [25], as well as bronchodilatory and
respiratory stimulant actions to help support respiratory health
[18].
Although several publications have detailed the chemical com-
position of A. zeylanica, only a paucity of reports on its safety exists
[2,5,7,22] and consequently, safe dosage and frequency of use lev-
els have not been established. Furthermore, the actual amounts of
A. zeylanica used in dietary supplements are often omitted from
the product labels. These shortcomings leave consumers unaware
of the potential hazards of taking dietary supplements containing
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f A. zeylanica, we performed a series of in vitro cellular tests that
peciﬁcally address the potential of A. zeylanica to adversely affect
he kidney. The kidneys are a common target of toxicity due to their
ole in ﬁltering xenobiotics from the plasma and excreting them
s waste products in the urine [16]. The glomerular ﬁltrate ﬂows
hrough the proximal and distal convoluted tubules before being
irected to the collecting ducts, ureter and bladder for subsequent
limination from the body [16]. The proximal tubule, in particu-
ar, is vulnerable to toxins present in the glomerular ﬁltrate, as it
an concentrate solutes to levels higher than those present in the
lood. To explore the possibility that A. zeylanica can induce prox-
mal tubule nephrotoxicity, we exposed human proximal tubule
ells directly to A. zeylanica and performed a series of in vitro cellular
ests to evaluate its potential association with acute toxic effects.
. Materials and methods
.1. Chemical characterization of A. zeylanica leaf extract
A crude methanol-extract of A. zeylanica leaf was  provided in
yophilized form from the University of Mississippi National Cen-
er for Natural Products Research (NCNPR, University, MS)  and was
tored in the dark at 4 ◦C in a vacuum chamber. Dried extract was
issolved in 5% acetonitrile in water to a ﬁnal concentration of
.1 mg/ml. Sample (1 l for MS,  3 l for MS/MS) was  injected into
n Agilent 1260 UPLC and chromatographed on an Agilent Poroshell
20 EC-18 column (3.0 × 50 mm,  2.7-micron particle size). Solvent
 was 0.1% formic acid in water, and solvent B was 0.1% formic acid
n acetonitrile. The initial solvent was 5% B with a 3 min  hold. The
olvent mix  was then programmed to 30% B at 7 min, then to 95%B
t 10 min. Column efﬂuent was analyzed on an Agilent 6520 QTof,
igh resolution mass spectrometer. Sample was analyzed in posi-
ive ESI mode with a capillary voltage of 4000 V. Compounds were
dentiﬁed from exact mass and MS/MS  spectra by comparison with
ublished data [9,24].
.2. Cell culture and treatments
Human kidney HK-2 cells (ATCC, Manassas, VA) were grown in
eratinocyte-SFM media supplemented with 5% FBS, 0.005 g/ml
hEGF, and 0.05 mg/ml  bovine pituitary extract (all from Invitro-
en, Carlsbad, CA) at 37 ◦C in a 5% CO2 humidiﬁed atmosphere.
K-2 cells are adult human proximal tubule cells that were trans-
ormed using HPV E6/E7 genes [23]. Cells were enumerated by
rypan blue dye (Invitrogen) exclusion and seeded at a density of
 × 104 cells per 100 l per well in 96-well plates, whose perimeter
ells were ﬁlled with 100 ul of sterile water to avoid evaporation
ffects in the inner wells. Stock treatment solutions of A. zey-
anica,  nephrotoxicant (positive control) cis-diamineplatinum(II)
ichloride (cisplatin) (Sigma, St. Louis, MO), and nephroprotectant
negative control) valproic acid (Sigma) were prepared using DMSO
nd diluting this mixture with media (for a ﬁnal DMSO concentra-
ion of ≤0.4% in media). Following overnight incubation, cells were
reated in triplicate for 24 h at the following dosages: 0, 12.3, 37,
11, 333, and 1000 g/ml.
.3. Cytotoxicity assay
Determination of treatment-related cytotoxicity was performed
n triplicate using the established CellTiter-Glo Cell Viability Assay
Promega, Madison, WI). This assay is based on luminescence emis-
ion to quantitate cellular ATP levels, which is directly proportional
o cell viability. Following the manufacturer’s guidelines, treated
ells seeded in black-wall, clear bottom 96-well plates were equi-
ibrated to room temperature for 30 min. During this incubation, Reports 3 (2016) 15–20
water in the perimeter wells were replaced with 100 l of treat-
ment or media only controls. Next, 100 l of CellTiter-Glo working
solution were added to each well and plates were placed on an
orbital shaker for 2 min  to induce cell lysis, and then incubated for
an additional 10 min  before being read on an OMG  Fluorostar plate
reader (BMG LABTECH, Ortenberg, Germany) to measure the levels
of luminescence.
2.4. Reactive oxygen species assay
Reactive oxygen species (ROS) production was measured in
triplicate using the ROS-Glo H2O2 luminescence-based detection
system (Promega) and data were normalized to cell viability. Based
on the manufacturer’s instructions, treated cells were incubated
with H2O2 substrate for the remaining 5 h of their 24-h treatment
at 37 ◦C in a 5% CO2 humidiﬁed atmosphere. Following, ‘Detection
Reagent’ was added and samples were incubated at room temper-
ature for at least 20 min  before luminescence was read on an OMG
Fluorostar plate reader.
2.5. Mitochondrial membrane potential assay
Mitochondrial membrane potential (MMP)  changes were
evaluated in triplicate using the ratiometric dye JC-10 (Enzo, Farm-
ingdale, NY). Lyophilized JC-10 was  reconstituted using HBSS and
diluted further to achieve a working solution of 20 M.  Treated cells
were incubated with JC-10 working solution dye for an interval of
2 h before being rinsed twice in HBSS, and ﬁnally being overlaid
with 100 l of HBSS. Plates were read using an OMG  Fluorostar
plate reader to measure emission at 520 and 590 nm following exci-
tation at 485 nm.  Natural auto-ﬂuorescence levels from treatments
or media alone were insigniﬁcant.
2.6. Nephrotoxicity biomarker assays
Cell culture supernatants from HK-2 cells treated for 24 h with
A. zeylanica, cisplatin, and valproic acid at high and low doses of 333
and 111 g/ml, respectively, were assayed for levels of nephrotoxi-
city biomarkers: albumin, beta-2-microglobulin (B2 M),  cystatin C,
kidney injury-1 (KIM-1) using the Human Kidney Toxicity Panel 1
and 2 kits (Bio-Rad, Hercules, CA). Following the manufacturer’s
protocol, plates were blocked with 10 l of blocking reagent for 1 h
and washed twice using the Bioplex plate washer (Bio-Rad). Next,
30 l of sample, standard, and controls were added to their pre-
designated wells and incubated for 1 h. Plates were washed and
30 l of detection antibody were added for a ﬁnal incubation of
30 min. After a ﬁnal wash, the plate was read using a Luminex 200
instrument (Bio-Rad). Biomarker expression levels were normal-
ized to cell viability.
2.7. Statistics
Data calculations and analyses were performed using Microsoft
Excel and Prism (GraphPad, San Diego, CA). Student t-tests or 2-way
ANOVAs were used to determine whether dose-matched treatment
effects using A. zeylanica, cisplatin, and valproic acid were statisti-
cally signiﬁcant at P values less than 0.01 or 0.001 as indicated.
3. Results
3.1. Analytical chemical characterization of A. zeylanica leaf
extractLC-high resolution MS  identiﬁed 88 total molecular features of
which seven were characteristic quinazoline alkaloids of A. zey-
lanica (Fig. 1). Compounds were putatively identiﬁed from exact
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Fig. 1. Extracted total compound chromatogram from chemical characterization of the A. zeylanica extract by LC-high resolution mass spectroscopy. Compound identiﬁcation
was  made by matching exact mass and MS/MS proﬁle with that of known components of A. zeylanica [9,24]. (1) vasicinol, (2) 5-hydroxyvasicine, (3) vasicine, (4) vasicine
glycoside, (5) 5-methoxyvasicine, (6) vasicinone, (7) adhatodine.





















Fig. 3. (a) ROS production and (b) MMP  loss following treatment of HK-2 with A. zey-alproic acid (ﬁlled circles) slightly reduces cell viability. Dashed line represents
ell viability of non-treated cells. Dashed line indicates ‘No treatment’ baseline ATP
evels. *, A. zeylanica vs. other treatments, P < 0.001.
ass and MS/MS  spectra as: vasicinol, 5-hydroxyvasicine, vasicine,
asicine glycoside, 5-methoxyvasicine, vasicinone, and adhatodine
Fig. 1). Vasicine was the major quinazoline alkaloid in the extract
ccounting for 85% of the peak area of the total identiﬁed alkaloids
nd 58% of the total chromatographic peak area.
.2. Direct exposure to A. zeylanica reduces cell viability at high
reatment doses
To assess the relative toxicity of direct exposure of HK-2 cells,
o A. zeylanica, cisplatin, or valproic acid for 24 h, we  performed
n established cell viability assay that is based on measuring ATP
evels in culture. As shown in Fig. 2, the levels of ATP in HK-2
ell cultures treated with A. zeylanica closely match the levels in
ells exposed to the nephroprotectant valproic acid up to the treat-
ent concentration of about 200 g/ml. Within this concentrationange, treating HK-2 cells with the nephrotoxicant cisplatin yielded
 steep reduction in cell viability relative to A. zeylanica starting at
ust 11 g/ml (P < 0.01) and actually decimated the cells at con-
entrations of about 200 to 1000 g/ml. Interestingly, when the A.
lanica (open circles), cisplatin (open squares), or valproic acid (ﬁlled circles). Changes
in  MMP  were calculated as a ratio of ﬂuorescence emission at 520 nm:590 nm.  *, A.
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eylanica treatment concentrations reached 1000 g/ml, the via-
ility of treated HK-2 cells dropped drastically to match those of
isplatin. By contrast, only a slight decrease in HK-2 cell viability
as detected relative to A. zeylanica (P < 0.001) when cells were
reated with 1000 g/ml of valproic acid. Based on these results,
he predicted lethal concentration 50 (LD50) for A. zeylanica is
03.7 g/ml, which is an intermediary value relative to that of cis-
latin, 12.1 g/ml, and valproic acid, 7187.0 g/ml.
.3. A. zeylanica exposure is associated with dose-dependent loss
f mitochondrial membrane potential
To gain an understanding of the reasons why cell viability was
ot signiﬁcantly compromised until the highest treatment dose
f 1000 g/ml was tested, we followed two approaches. First, we
nvestigated the levels of reactive oxygen species (ROS) produc-
ion as a function of treatment dose, since the cells that rely on
itochondrial respiration release ROS as a byproduct and that any
igniﬁcant elevation in their levels could be highly damaging to
ells. As shown in Fig. 3a, we found that the trends in ROS pro-
uction following treatment with A. zeylanica, cisplatin, or valproic
cid closely matched those of cell viability. Speciﬁcally, cisplatin
nduced increasing levels of ROS over the range of doses tested,
hereas valproic acid consistently produced relatively lower lev-
ls within this testing range. By contrast, ROS production by A.
eylanica also consistently led to relatively low ROS output lev-
ls compared to cisplatin (P < 0.01), until the 1000 g/ml treatment
ose was applied. HK-2 cells generated a surge in ROS production
hat greatly surpassed those of valproic acid (P < 0.01) and nearly
xactly matched those of cisplatin instead. These results mirror the
rends in cell viability we found, prompting a further exploration
nto the effects of these treatments on the mitochondrial toxicity
f HK-2 cells.
To study, the effect of A. zeylanica on global changes in mitochon-
rial health in human proximal tubule cells, we sought to use an
stablished assay that measures changes in mitochondrial mem-
rane potential (MMP), since mitochondrial damage is preceded
y MMP  loss. After directly treating HK-2 cells for 24 h with A.
eylanica, cisplatin, or valproic acid, we performed JC-10 ﬂuores-
ence assays to measure the relative levels of mitochondria whose
MPs  have been compromised to those with intact MMPs. JC-
0 dye selectively passes through mitochondrial membranes that
ave been damaged and yields a ﬂuorescence emission spectrum
peak emission value at 520 nm)  that is distinct from that of JC-
0 molecules that have not entered mitochondria (peak emission
alue at 590 nm). By comparing the ratio of unhealthy to healthy
itochondria, we monitored the shifts in mitochondrial popula-
ions undergoing damage following dose-dependent treatments.
urprisingly, we uncovered a new pattern of toxicity associated
ith A. zeylanica (Fig. 3b). Whereas increasing concentrations of
alproic acid only mildly affected mitochondrial health until the
00 g/ml testing dose, treating HK-2 cells with either A. zeylan-
ca or cisplatin led to nearly indistinguishable steady elevations
n the relative subsets of damaged mitochondria throughout the
–1000 g/ml dose range tested. At this maximum treatment con-
entration of 1000 g/ml, valproic acid did yield an increase in
he ratio of damaged to healthy mitochondria, consistent with its
ffects on cell viability at this treatment dose.
.4. Biomarkers of nephrotoxicity are elevated in HK-2 cells
xposed to A. zeylanicaHaving established that A. zeylanica has the ability to induce cel-
ular and mitochondrial toxicity in human proximal tubule cells,
e investigated the speciﬁc nephrotoxic potential of this botani-
al extract. Several biomarkers of kidney-speciﬁc injury have been Reports 3 (2016) 15–20
established, validated, and qualiﬁed for use by the FDA [6]. Among
these biomarkers, we selected those that measure levels of damage
to human proximal tubule cells for use in this study: (1) albumin,
(2) 2-microglobulin (B2 M),  (3) cystatin C, and (4) kidney injury
molecule-1 (KIM-1). Using a sensitive Luminex detection method,
we quantitatively measured the levels of these biomarkers in the
culture supernatants of HK-2 cells directly exposed to A. zeylanica,
cisplatin, or valproic acid at two treatment doses. The ﬁrst dose at
which we  assessed biomarker levels was the relatively low dose
of 111 g/ml. A. zeylanica treatment at this concentration yielded
cell viability levels that were not signiﬁcantly deviant from those
of valproic acid, but that were signiﬁcantly higher than those of cis-
platin. We  found that treatment of HK-2 cells with A. zeylanica at
111 g/ml generated a biomarker signature that was nearly iden-
tical to that of valproic acid, which in turn, was  only slightly higher
(but not statistically signiﬁcant) than that of ‘no treatment’ baseline
control. The biomarker levels produced following treatment of cells
with 111 g/ml of cisplatin were, however, associated with rela-
tively high values for albumin, B2 M (P < 0.01), cystatin C (P < 0.01),
and KIM-1 (P < 0.01).
The second dose we  tested for biomarker level evaluation was
333 g/ml, as this was  the ﬁrst tested dose that produced the ﬁrst
indication that A. zeylanica had the potential to compromise cell via-
bility. As shown in Fig. 4a, the levels of all four biomarkers measured
in the supernatants of A. zeylanica-treated HK-2 cells were indistin-
guishable from those of valproic acid-treated cells, but signiﬁcantly
lower than those of cisplatin (P < 0.01). Even though A. zeylanica
treatment at 333 g/ml produced a biomarker signature that was
very similar to that of valproic acid, it nevertheless yielded levels
that were above our ‘no treatment’ baseline, reaching signiﬁcance
only in the case of B2 M (P < 0.01).
4. Discussion
As dietary supplements continue to increase in popularity,
scientiﬁc efforts directed towards evaluating the safety of their
ingredients will help allay potential concerns among consumers.
In this study, we  assessed the potential of A. zeylanica to adversely
affect cells of the proximal convoluted tubule. We  employed a vari-
ety of in vitro techniques to screen for potential toxicological effects
of A. zeylanica on human renal proximal tubule cells, using HK-2
cells as a cellular model. Given the wide range of reported uses of
this herb in traditional medicine [12], we expected that A. zeylanica
also had the potential to adversely affect multiple target organs,
including the kidney. Based on our cell viability testing results it
was determined that A. zeylanica is not signiﬁcantly toxic under
conditions of direct exposure for 24 h, until the treatment dose
reaches very high values of around 1000 g/ml. The mechanism
of this action may  be explained by the surge in ROS production that
was observed exclusively at this high dose. Indeed, the damaging
effects of excessive ROS molecules are well documented and were
likely a major contributor to compromising cell viability [20]. Inter-
estingly, we  also detected general mitochondrial damage that was
present at levels directly proportional to the treatment dose. This
result suggests that A. zeylanica has the ability to alter mitochon-
drial structure and/or function in ways that do not immediately
lead to cell death, but could still lead to overall cell damage over
time [20].
Having established that A. zeylanica has limited potential to
injure cells, we checked for early signs of proximal tubule dam-
age to uncover a possible nephron-speciﬁc toxicity signature for
A. zeylanica using the biomarkers albumin, B2 M,  cystatin C, and
KIM-1 [6,10,27]. Consistent with our cell viability data, all four
tested biomarkers revealed that A. zeylanica was as innocuous as
valproic acid towards HK-2 cells at the treatment doses of 111


























uig. 4. Changes in biomarkers of nephrotoxicity in HK-2 cell cultures following (a) 
ulture supernatants were harvested at 24 h post-treatment and assayed by Bio-pl
ere  normalized to cell viability. *, A. zeylanica vs. other treatments, P < 0.01.
nd 333 g/ml. Of note, some variations in the B2 M values were
bserved among valproic acid treatment groups, but were still rel-
tively low. Our positive control results with cisplatin did show the
xpected elevations in biomarker levels. Our results using cisplatin
re consistent with other publications that report the effects of
enal injury using HK-2 cells as an in vitro cellular system [15,26,28].
f note, our ﬁndings are particularly signiﬁcant, as the 333 g/ml
ose was the ﬁrst treatment concentration that indicated that A.
eylanica could deviate from its trend of not compromising cell
iability. Taken together, our screening study did not ﬁnd strong
vidence for A. zeylanica being a highly acute nephrotoxic herb
nder the experimental conditions of our investigation.
When undertaking this type of screening study, careful con-
ideration went into choosing the appropriate cellular model. We
elected HK-2 as our cellular in vitro model of choice because it
aptures many key features of primary human proximal tubule
ells, including cell morphology, brush border enzyme expression,
nd metabolic phenotype [23]. The use of HK-2 as a model of
uman proximal tubule cells has been validated by other research
roups to accurately model kidney injury when exposed to nephro-
oxicants [26,30,31]. This point is very important, as we  included
isplatin as our positive (nephrotoxic) control and valproic acid as
ur negative (nephroprotectant) control and the data we generated
sing these controls are consistent with data from other groupsd (b) high treatment doses with A. zeylanica, cisplatin, and valproic acid. HK-2 cell
ay for levels of KIM-1, albumin, cystatin C, and B2 M.  Biomarker expression levels
using similar techniques with HK-2 cells [13,26]. Having the two
controls in our study allowed us to gauge relative levels of toxicity
for A. zeyanica against two references, lending strong conﬁdence in
our results.
Our study is the ﬁrst to evaluate the in vitro nephrotoxicity of
A. zeylanica with a speciﬁc focus on the proximal tubules. Although
no other study has directly investigated its nephrotoxic potential,
recent evidence by other researchers shows that A. zeylanica can
help protect against the nephrotoxic effects of gentamycin in vivo
[17]. Additionally, there are several publications describing the
in vivo effects of A. zeylanica with respect to its reproductive toxic-
ity in rodent models. Among these studies, there are discrepancies
between their conclusions, with some research showing that A. zey-
lanica has the ability to prevent embryonic implantation and even
serve as an abortifacient in rat experiments designed to administer
daily extract doses as high as 325 mg/kg/day over the course of nine
days [5], while others show no reproductive or other major adverse
effects in rat and monkey studies [7,21,22]. Although vasicine is a
major alkaloid component of A. zeylanica, it is not yet clear to what
degree its presence contributes to any potential toxicities exhibited
by this herb.Further research will be needed to deﬁne the conditions under
which this botanical extract could become nephrotoxic. Full com-




































[31] L. Zhang, X. Mu,  J. Fu, Z. Zhou, In vitro cytotoxicity assay with selected
chemicals using human cells to predict target-organ toxicity of liver and0 M.E. Mossoba et al. / Toxi
aluable towards this goal and would also help establish safe
osage levels. Addressing questions about the safety of A. zeylanica
n combination with other ingredients present in such supplement
roductions would be important future directives. Overall, based
n our in vitro ﬁndings it appears that A. zeylanica may  lack potent
roximal tubule nephrotoxicity, however further in vivo studies are
eeded to establish its metronomic effects in long-term settings,
specially in the setting of repeated dose exposure.
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